The expansion of the drug discovery CRO market highlights the need to minimize costs and timelines in pharmaceutical drug development. Discover how SARomics Biostructures can help with this!
It was a year marked by the most significant changes in recent memory: a new home for the company, four new team members, new collaborations, new publications, a revamped homepage, and a greatly expanded list of off-the-shelf structures.
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s unique DNA-encoded library (DEL) screening technology.
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
This post provides the latest company news update. It would be fair to keep our former clients, followers, and anybody…
What makes a successful services company? What is our strength, and how to define our selling points? We arrive at a list of 8 essential selling points defining the success of SARomics Biostructures.
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious…
Since our first trip into the realm of EU projects with the KINOMED project, we have engaged in 7 different…
SARomics Biostructures is continuing its expansion with new team members, an updated company logotype, expanded laboratory and office space, and…